Compare Novo Nordisk A/S (NVO) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs S&P Global Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while S&P Global Inc trades at $431.29 (market cap $132.71B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | SPGI | |
|---|---|---|
Market Cap | $220.53B | $132.71B |
Sector | Health | Financials |
52-Week High | $71.70 | $534.79 |
52-Week Low | $35.29 | $370.42 |
Enterprise Value | $239.49B | $144.68B |
Dividend Yield | 3.63% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
S&P Global (SPGI) trades at $431.26, down 4.34% on the day, amid a generally bullish technical setup with strong analyst support. The company reported robust fundamentals with 2025 revenue of $15.34B and net income of $4.47B, yielding a 30.36% net margin. Recent corporate developments include the spin-off of its mobility business and new product launches in digital asset indexing and ETF analytics, signaling strategic focus and innovation.
The outlook remains positive given strong profitability, recurring revenue model, and Wall Street's consensus price target of $532.10, implying significant upside. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Earnings growth and AI-driven data demand present the primary catalysts for shareholder value appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
